Skip to main content
MedinCell S.A. logo

MedinCell S.A. — Investor Relations & Filings

Ticker · MEDCL ISIN · FR0004065605 LEI · 969500R79U6PXCL2FF46 PA Manufacturing
Open in API
Filings indexed 522 across all filing types
Latest filing 2024-02-01 Report Publication Anno…
Country FR France
Listing PA MEDCL

About MedinCell S.A.

https://www.medincell.com/en/

MedinCell S.A. is a pharmaceutical company at the commercial stage that specializes in the development of long-acting injectable (LAI) therapies. The company's core is its proprietary BEPO® technology platform, which enables the controlled and sustained release of active pharmaceutical ingredients over periods ranging from days to months after a single injection. This technology forms a fully biodegradable depot in situ, designed to improve treatment efficiency, enhance patient compliance, and increase the global accessibility of medicines. MedinCell develops a portfolio of LAI products across various therapeutic areas, including psychiatry, advancing its pipeline through both internal research and strategic partnerships with other pharmaceutical organizations.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Report Publication Announcement Classification · 98% confidence The document is titled "Publication of the 2024 financial calendar" and explicitly lists future dates for key corporate events, including the 'Annual results 2023-2024', 'General Meeting', and 'Half-Year results 2024-2025'. This document is an announcement about the schedule of future corporate reports and meetings, not the reports themselves. Since it is an announcement regarding the publication schedule of reports, it fits best under the 'Report Publication Announcement' (RPA) category. The document length (2320 chars) is short, supporting the RPA classification over classifying it as the actual report (like 10-K or IR).
2024-02-01 English
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 98% confidence The document is titled "Publication du calendrier financier 2024" (Publication of the 2024 financial calendar) and lists future dates for key corporate events, specifically mentioning the 'Résultats annuels 2023-2024' (Annual results), 'Assemblée Générale' (General Meeting), and 'Résultats semestriels 2024-2025' (Half-year results). Since the document's primary function is to announce *when* future reports and meetings will occur, rather than containing the full content of those reports (like a 10-K or IR), it fits the definition of announcing the publication of reports. Given the short length (2436 chars) and the nature of announcing future report releases, the most appropriate classification is Report Publication Announcement (RPA).
2024-02-01 French
Inside Information / Other news releases
Regulatory Filings Classification · 99% confidence The document is a press release dated January 31, 2024, issued by MedinCell, providing updates on its partner Teva's guidance for UZEDY revenue and the progress of the Olanzapine LAI Phase 3 trial. It contains key financial highlights (guidance, milestones) and clinical updates, but it is not the full quarterly report (IR) or the official annual report (10-K). It is an initial announcement of key financial performance indicators and business updates, which aligns best with the definition of an Earnings Release (ER). It is not a transcript (CT), a formal presentation (IP), or a simple announcement of a report publication (RPA).
2024-01-31 English
Informations privilégiées / Autres communiqués
Earnings Release Classification · 98% confidence The document is a press release dated January 31, 2024, issued by MedinCell, detailing updates on its partner Teva's sales forecast for UZEDY™ and the progress of the long-acting injectable olanzapine (mdc-TJK) Phase 3 trial. It contains key financial highlights (revenue forecast, royalties received) and operational updates, but it is not the full quarterly/annual financial report (10-K or IR). It is an initial announcement of key results and forward-looking statements, which aligns best with an Earnings Release (ER). It is too detailed and specific to be a simple Report Publication Announcement (RPA) or a general Regulatory Filing (RNS), as it contains management commentary and specific financial guidance. FY 2024
2024-01-31 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a monthly regulatory disclosure required by Article 223-16 of the AMF General Regulation, detailing the number of shares and voting rights for MedinCell. This type of filing is a standard regulatory requirement for listed companies in France to update the market on capital structure changes. It does not fit into specific categories like 'Share Issue' (which would be a specific event) or 'Major Shareholding' (which would be a third-party notification), making 'Regulatory Filings' (RNS) the most appropriate classification for this recurring administrative disclosure.
2024-01-11 French
Inside Information / Other news releases
Capital/Financing Update Classification · 95% confidence The document is titled "Half-year liquidity contract statement for MEDINCELL" and is dated January 11, 2024, reporting data as of December 31st, 2023. It details the status and activity of a liquidity contract (share buyback/stabilization agreement) with Kepler Cheuvreux, referencing compliance with AMF Decision N°2021-01. This type of filing reports on specific financial/market operations (liquidity management) rather than comprehensive financial results (like 10-K or IR) or management changes. It is a periodic statement related to capital/financing activities, but more specifically, it is a required disclosure regarding market operations. Given the options, this specialized report on share liquidity management fits best under Capital/Financing Update (CAP) as it directly relates to the management of the company's share capital structure and market presence, or potentially Regulatory Filings (RNS) as a mandatory disclosure. However, since it is a specific statement about a contract related to share activity, CAP is a strong fit. If we consider the nature of liquidity contracts as a form of capital management/market support, CAP is appropriate. If we look at the definitions, it is not a standard financial report (IR, 10-K), nor a dividend notice (DIV), nor a transaction in own shares (POS, which usually reports the actual buy/sell transactions, not the contract statement). Since it is a formal, periodic statement required by regulation (AMF), and relates to share capital management, I will classify it as Capital/Financing Update (CAP).
2024-01-11 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.